Soon, insulin inhalers in Indian market

Exubera is considered a short or rapid acting insulin. In clinical studies, Exubera reached peak concentration levels faster than some insulins administered by injection. Thus, this form of insulin would begin working within the body faster than insulin that is injected. Type 1 and 2 diabetics will still need an injection of longer acting insulin to maintain a basal level for a 24 hour period.

Experts, however, say that it will be a costly affair and benefit only a small fraction of people. 8220;It can be afforded by only certain section of people as it will cost about Rs 6,000 a month, excluding the other costs. The standard injectable insulin procedure costs much less,8221; said Dr Anoop Misra, director and head, Department of Diabetes and Metabolism, Fortis Group of Hospitals.

8220;It8217;s a great advantage in delivery of insulin as diabetics have a great fear of injections,8221; added Dr Misra.

As effective as short-acting insulin lasts six to eight hours, the inhaler is effective in achieving the glucose targets after meal.

However, it cannot be replaced for all diabetics. 8220;This therapy cannot be given to smokers and those having lung diseases,8221; Dr Misra added.